ImaginAb Inc. and A*STAR Jointly Develop Recombinant Antibody Fragment for Diagnostic Imaging
June 3, 2010
Singapore, 3rd of June, 2010 - ImaginAb, Inc. and Singapore’s Agency for Science, Technology and Research (A*STAR) have concluded a research collaboration agreement to re-engineer a therapeutic antibody asset against a promising oncology target – PRL3 – into an imaging agent as a first step towards better understanding the biology of this target in humans.
Led by Prof Sir David Lane, Chief Scientist at A*STAR, the collaboration will tap on the cutting- edge imaging technologies at the Singapore Bioimaging Consortium (SBIC) under A*STAR. “This is very promising biology, and we are pleased to work with Sir David Lane and his team to explore the role of imaging in the development of this asset”, said Dr. Anna Wu, Founder and Chief Scientific Advisor to ImaginAb.
ImaginAb’s CEO, Dr. Christian Behrenbruch commented, “We are extremely impressed with what A*STAR has created at Biopolis and we have undertaken this project jointly with them as a way to explore Singapore’s potential as a key hub for our pre-clinical imaging and pharma services business. This antibody was discovered in Singapore. The protein will be produced in Singapore by A-Bio Pte Ltd., and the radiochemistry and pre-clinical imaging studies will be conducted at the Singapore Bioimaging Consortium (SBIC). This is a powerful demonstration of the extent of the local biotech and imaging capabilities in Singapore.”
Prof Sir George Radda, Chairman of the SBIC, which is conducting the imaging work for the collaboration, added, “SBIC is pleased to be participating in the PRL3 project. This is precisely the type of joint industry-academic collaboration that demonstrates the strength of our imaging platform to the biopharma industry”. Said Prof Sir Lane, “Molecular imaging, and particularly PET, is an extremely powerful tool for the in vivo understanding of biology in a rapid and cost-effective fashion. As we further develop our biology, we will increasingly turn to technologies such as ImaginAb’s antibody fragments to make important early development decisions and we are delighted to be working with Anna and her team”.
About the Singapore Bioimaging Consortium (SBIC)
The Singapore Bioimaging Consortium (SBIC) is a research consortium of the Agency for Science, Technology and Research (A*STAR) in Singapore. SBIC aims to build a coordinated national programme for imaging research, bringing together substantial strengths in the physical sciences and engineering and those in the biomedical sciences. It seeks to identify and consolidate the various bioimaging capabilities across local research institutes, universities and hospitals, in order to speed the development of biomedical research discoveries. SBIC has built up an extensive network of partners, through collaborations and joint appointments with research institutes, university and clinical departments, and the industry. Its partners include the Singapore Institute for Clinical Sciences, the NUS Chemistry Department, the National Cancer Centre, Duke-NUS, Bruker, GlaxoSmithKline, Takeda, and Schering Plough.
For more information about SBIC, please visit www.sbic.a-star.edu.sg.
About the Agency for Science, Technology and Research (A*STAR)
The Agency for Science, Technology and Research (A*STAR) is the lead agency for fostering world-class scientific research and talent for a vibrant knowledge-based and innovation-driven Singapore. A*STAR oversees 14 biomedical sciences, and physical sciences and engineering research institutes, and nine consortia & centres, which are located in Biopolis and Fusionopolis, as well as their immediate vicinity. A*STAR supports Singapore's key economic clusters by providing intellectual, human and industrial capital to its partners in industry. It also supports extramural research in the universities, hospitals, research centres, and with other local and international partners.
For more information about A*STAR, please visit www.a-star.edu.sg.
Founded in 2007 by UCLA Faculty (Dr. Rob Reiter and Dr. Anna Wu), ImaginAb, Inc. is a biotechnology company specializing in the development of engineered antibody fragments for diagnostic imaging and radioimmunotherapy. The company has a significant pipeline of clinical imaging agents under development oriented towards unmet needs in cancer and immunology. ImaginAb is also developing a range of pre-clinical (animal imaging) reagents for use with microPET and microSPECT systems and partners on a selective basis with biopharmaceutical companies with an interest in developing companion imaging agents for therapeutic antibody products.